Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs

Saxenda in Ohio (2026)

liraglutide · GLP-1 weight management · Ohio-specific guide

Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.
Last verified by glpzoom Editorial Team against primary sources

About Saxenda

FDA-approved daily injectable liraglutide for chronic weight management. Older-generation GLP-1, daily dosing.

See the full Saxenda review for dosing, efficacy data, side effects, and the full pharmacy + telehealth program comparison.

Insurance coverage for Saxenda in Ohio

Ohio Medicaid does not cover GLP-1s for weight loss. Diabetes coverage available with prior authorization.

CarrierSaxenda statusDetail
AetnaCovered (prior auth required)Aetna's Saxenda coverage has narrowed as newer GLP-1s have entered the market; many plans now require step-through to Wegovy first.
Blue Cross Blue ShieldLimited coverageSaxenda coverage is more limited as newer GLP-1s have entered. Some Blues still cover with prior auth.
UnitedHealthcareLimited coverageSaxenda coverage on UHC is narrower than newer GLP-1s; step-through requirements common.
CignaLimited coverageLimited coverage; step-through to newer GLP-1s often required.
HumanaNot coveredSaxenda is generally not on Humana commercial formularies in 2026.
Kaiser PermanenteLimited coverageLimited Kaiser coverage as newer agents have entered.
AnthemLimited coverageLimited; newer GLP-1s typically preferred.
MedicareNot coveredMedicare does not cover Saxenda for weight loss (same statutory exclusion as Wegovy/Zepbound).
MedicaidVaries by planState coverage of Saxenda varies; coverage is often more permissive than Wegovy because Saxenda is older but is being deprioritized as newer agents enter.
TRICARELimited coverageLimited; newer GLP-1s preferred under the weight management program.

Telehealth and prescribing in Ohio

Ohio State Medical Board permits interstate telehealth. Active in IMLC.

Major platforms with active Ohio availability that may prescribe Saxenda: Ro Body, Hims Weight Loss, PlushCare. Each platform varies in which drugs they prescribe, insurance handling, and clinical model. See our platform comparisons for details.

Compounded Saxenda in Ohio

Ohio Board of Pharmacy enforcing FDA 2026 guidance with moderate pace.

See our guide on the FDA compounding shutdown for the national context.

Saxenda in Ohio — frequently asked

Is Saxenda legal in Ohio?+

Yes. Saxenda (liraglutide) is FDA-approved and legal in all 50 US states including Ohio. State-level differences appear in insurance coverage, telehealth prescribing rules, and (for GLP-1s) compounding pharmacy access — not in the underlying legality of the medication itself.

Can I get Saxenda via telehealth in Ohio?+

Ohio State Medical Board permits interstate telehealth. Active in IMLC. Major US telehealth platforms operating in Ohio that may prescribe Saxenda include Ro Body, Hims Weight Loss, PlushCare. Each platform handles insurance and prescribing differently — see our platform comparisons for details.

Does Ohio Medicaid cover Saxenda?+

Ohio Medicaid does not cover GLP-1s for weight loss. Diabetes coverage available with prior authorization. For Saxenda specifically: State coverage of Saxenda varies; coverage is often more permissive than Wegovy because Saxenda is older but is being deprioritized as newer agents enter.

What's the cheapest way to get Saxenda in Ohio?+

For Saxenda in Ohio, the three main paths are: (1) insurance with prior authorization if your plan covers it (often $0-$25 copay), (2) manufacturer self-pay programs (NovoCare for Wegovy/Ozempic, LillyDirect for Zepbound/Mounjaro/Orforglipron), (3) telehealth bundles that include the medication. Direct-pay manufacturer programs typically beat retail pharmacy prices in 2026.

Is compounded Saxenda still available in Ohio?+

Ohio Board of Pharmacy enforcing FDA 2026 guidance with moderate pace. The FDA proposed permanently ending large-scale 503B compounding of semaglutide and tirzepatide on April 30, 2026. Individualized 503A compounding for documented clinical need may continue in Ohio, but routine 'cheaper alternative' compounding is being shut down.

Related

We may earn a commission when you click links to partners. Affiliate disclosure.